Market Overview

Benzinga's Top Initiations

Share:
Benzinga's  Top Initiations

 

  • Brean Capital initiated coverage on Lions Gate Entertainment Corp. (USA) (NYSE: LGF) with a Buy rating. The price target for Lions Gate is set to $27. Lions Gate shares gained 0.73 percent to $20.63 in pre-market trading.
  • Analysts at Goldman Sachs initiated coverage on Cemex SAB de CV (ADR) (NYSE: CX) with a Buy rating. Cemex shares rose 2.42 percent to close at $8.48 on Friday.
  • Analysts at Imperial Capital initiated coverage on Hawaiian Holdings, Inc. (NASDAQ: HA) with an Outperform rating. The price target for Hawaiian Holdings is set to $58. Hawaiian Holdings shares gained 0.66 percent to close at $47.60 on Friday.
  • Drexel Hamilton initiated coverage of CBS Corporation (NYSE: CBS) with a Buy rating. CBS shares rose 0.35 percent to close at $52.22 on Friday.
  • Macquarie initiated coverage on Kaiser Aluminum Corp. (NASDAQ: KALU) with an Outperform rating. Kaiser Aluminum shares rose 0.01 percent to close at $85.63 on Friday.
  • Analysts at Citi initiated coverage on L-3 Communications Holdings, Inc. (NYSE: LLL) with a Buy rating. The price target for L-3 Communications is set to $174. L-3 Communications shares rose 0.31 percent to $150.35 in pre-market trading.
  • Analysts at Goldman Sachs assumed Dollar General Corp. (NYSE: DG) with a Neutral rating. The price target for Dollar General is set to $84. Dollar General shares fell 0.71 percent to $72.80 in pre-market trading.
  • Analysts at UBS initiated coverage on Medpace Holdings Inc (NASDAQ: MEDP) with a Buy rating. The price target for Medpace Holdings is set to $35. Medpace Holdings shares gained 0.62 percent to $30.89 in pre-market trading.
  • Analysts at Pacific Crest initiated coverage of Ellie Mae Inc (NYSE: ELLI) with an Overweight rating. The price target for Ellie Mae is set to $124. Ellie Mae shares slipped 0.58 percent to close at $98.80 on Friday.
  • Analysts at Leerink Swann initiated coverage on Protagonist Therapeutics Inc (NASDAQ: PTGX) with an Outperform rating. The price target for Protagonist Therapeutics is set to $17. Protagonist Therapeutics shares declined 0.08 percent to close at $12.08 on Friday.

Latest Ratings for CX

DateFirmActionFromTo
Apr 2019DowngradesOverweightEqual-Weight
Apr 2019Initiates Coverage OnNeutral
Oct 2018MaintainsOverweightOverweight

View More Analyst Ratings for CX
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (CBS + CX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MSGNDowngrades
HUBBInitiates Coverage On160.0
CTREUpgrades25.0
GLNGMaintains27.0
SEMaintains45.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Summit Redstone Assumes Buy On Splunk, Sees Compelling Case For M&A

If Twitter Were An M&A Target, Who Would Want It?